AI Drug Discovery Tool
How does Insilico Medicine use artificial intelligence for drug discovery?
Insilico Medicine uses AI across its Pharma.ai platform to accelerate drug discovery and development. The platform integrates multi-omics target discovery and deep biology analysis to uncover lead-like molecules, design potential drugs, and predict the likelihood of clinical trial success. It also employs machine learning-based de-novo drug design and scalable engineering to discover and prioritize targets and molecules, while providing insights to optimize clinical trial design.
In addition, Insilico offers a family of AI-powered software for science, including Pharma.ai, PandaOmics, PandaOmics Box, Generative Biologics, Chemistry42, inClinico, Science42:DORA, PreciousGPT, and Nach01.
Our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative AI, significantly reducing the time and cost to bring life-saving medications to patients.
What are Insilico Medicine's notable AI-driven drug development achievements?
- Data presentations for ISM5411, a gut-restricted PHD1/2 inhibitor, at the 2026 Crohn’s & Colitis Congress, highlighting clinical, preclinical safety, and efficacy data.
- FDA IND approval for ISM8969, an AI-enabled potential best-in-class NLRP3 inhibitor.
- Global R&D collaboration with Lilly announced in March 2026.
- Public disclosures and milestones related to multiple assets and collaborations, including Menarini Group partnerships and advancements in oncology and cardiometabolic programs.
- Hong Kong IPO listing in late 2025 and ongoing investor and industry collaborations, including preclinical candidates like ISM6166 (Pan-KRAS) and ISM0676 (GIPR antagonist) and license activities with partners such as Menarini and Taigen.
These items reflect Insilico’s ongoing AI-enabled drug discovery efforts, clinical assets, and strategic collaborations as reported in its press releases and company communications.
What is the mission of Insilico Medicine?
Our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost to bring life-saving medications to patients.
Where are Insilico Medicine's offices located?
- Boston, Massachusetts, United States: 1000 Massachusetts Avenue, Suite 126, Cambridge, MA 02138
- Hong Kong: Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
- Abu Dhabi, United Arab Emirates: Level 6, Unit 08, Block A, IRENA HQ Building Masdar City
- Shanghai, China: 9F, Chamtime Plaza Block C, Lane 2889, Jinke Road, Pudong New Area, Shanghai
What AI platforms and products does Insilico offer?
Insilico provides a suite of AI-powered software for science, including:
- Pharma.ai: Generative AI software for drug discovery, scientific research & sustainability
- PandaOmics
- PandaOmics Box
- Generative Biologics
- Chemistry42
- inClinico
- Science42:DORA
- PreciousGPT
- Nach01
What is Nach01 and how does it help drug discovery?
Nach01 is Insilico’s foundation model designed to enable AI-native, enterprise-ready drug discovery workflows. It is integrated with Microsoft Discovery to enhance scalable, AI-driven drug discovery across the company’s platforms. This model is part of Insilico’s strategy to bring enterprise-grade AI to scientific research workflows.
How can I stay updated or contact Insilico?
- Visit Insilico’s News & Media sections (Press Releases, Media Coverage, Publications, Blog, Events) for the latest announcements.
- For investor updates, use the Investor Relations section to access webcasts, circulars, and email alerts.
- You can reach out via the general Contact Us channels listed on the site for inquiries and partnerships.
-2%20(1).webp)
